Office: Cambridge, MA

Executive Assistant:
Fressia Barbagelata
(617) 949-2177

Finny Kuruvilla, MD, PhD
Principal

Finny Kuruvilla, MD, PhD joined Clarus Ventures from the Broad Institute of Harvard and MIT where he led a collaborative effort with Affymetrix (NASDAQ: AFFX) in medical and population genetics.  

Previously, he completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. He received his M.D. from Harvard Medical School, his Ph.D. in chemistry and chemical biology from Harvard University, his master’s degree in electrical engineering and computer science from MIT, and his bachelor’s degree in chemistry from Caltech.

Dr. Kuruvilla represents Clarus Ventures on the Board of Directors of Nanostring (NASDAQ: NSTG), and is also a Board Observer for Catabasis, Lycera, Tetralogic, and Virdante.

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Private
Team: Scott Requadt
Finny Kuruvilla
Nicholas Galakatos

Catabasis Pharmaceuticals, Inc.

Catabasis is an early stage biopharmaceutical company led by experienced entrepreneurs that is developing NCEs that incorporate, and amplify the beneficial effects of, OMEGA-3 fatty acids. It is advancing multiple proprietary small molecule candidates for the treatment of metabolic disease and inflammation.

Catabasis Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Private
Team: Finny Kuruvilla
Dennis Henner

Cleave Biosciences

Cleave Biosciences is an early stage oncology therapeutics company focused on novel targets in cellular protein homeostasis pathways. Controlled largely by two distinct systems – the ubiquitin proteasome system and the autophagy system, these pathways are utilized by cancer cells for their growth and survival. 

The company secured a $42M Series A investment in October 2011.

Cleave Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Private
Team: Michael Steinmetz
Finny Kuruvilla
Dennis Henner

Lycera Corporation

Lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.  Lycera’s pipeline includes proprietary small molecules against two novel targets, a mitochondrial molecule that  is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the Th17 pathway.  Lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents.

Lycera Website

Fund: Clarus Lifesciences II, L.P.
Sector: Diagnostics & Tools
Status: False
Type: Public
Team: Finny Kuruvilla
William Young
Nicholas Galakatos

NanoString Technologies, Inc. (NASDAQ: NSTG)

Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.

NanoString Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Public
Team: Michael Steinmetz
Finny Kuruvilla
Dennis Henner

TetraLogic Pharmaceuticals, Inc. (NASDAQ: TLOG)

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company founded on a mechanism that has the potential to promote apoptosis, or programmed cell death, in cancer cells. Cancer cells are often resistant to apoptosis and Tetralogic’s lead molecule, a Smac-mimetic, may abrogate that resistance. The Smac-mimetic is currently in clinical trials for the treatment of cancer.

TetraLogic Website